In-depth analysis of US tech stocks, Federal Reserve rate decisions, S&P 500 trends, and macro economics. Expert stock market insights for US investors.
Halliburton stands as the world's second-largest oilfield services company. Based in Houston with dual headquarters in Dubai, this energy giant specializes in everything from drilling to hydraulic fracturing. Currently, the…
Spotify delivered explosive earnings in early November. The streaming giant surpassed revenue expectations, boasted margin expansion, and added 29 million subscribers. Stock climbed to $775 before settling around $645. This…
The cryptocurrency markets are experiencing severe turbulence. Bitcoin has crashed to $101,099 and Ethereum dropped to $3,363 as of November 4, 2025. Both assets marked their worst October performance in…
Nebius Group is transforming the AI infrastructure market right now. Moreover, this Amsterdam-based company has delivered a stunning 486% stock price increase over the past year. Furthermore, the stock currently…
Nevada's largest electric utility NV Energy serves 1.4 million customers across the state, but there's a critical fact you need to know. This company is no longer available for public…
AMC Entertainment currently trades at $2.69, down dramatically from its 52-week high of $11.88. Furthermore, the theater chain reports mixed signals despite recent operational improvements. Additionally, high debt levels and…
Looking at Compass Inc stock right now? You're probably wondering if this tech-enabled real estate giant is worth your attention. The short answer: Compass has posted record-breaking growth in 2025, with Q2…
BAC looks well-positioned for 2025. Earnings re-accelerated on strong investment banking activity, record net interest income, and disciplined costs. Moreover, analysts now see mid-teens upside over 12 months while credit…
DELTA Air Lines is crushing it in 2025. The airline stock delivered a massive 75.1% return this year. Moreover, it's trading at just 8.47 times earnings. This makes it one of…
AstraZeneca (AZN) is a large-cap, research-driven pharma leader with broad growth across oncology, cardiovascular–renal–metabolism, and respiratory–immunology, supported by rising U.S. focus, robust trial wins, and steady dividend credentials. Therefore, if…